作者
Dai Shimizu,Kenzui Taniue,Yusuke Matsui,Hiroshi Haeno,Hiromitsu Araki,Fumihito Miura,Mitsuko Fukunaga,Kenji Shiraishi,Yuji Miyamoto,Seiichi Tsukamoto,Aya Komine,Yuta Kobayashi,Akihiro Kitagawa,Yasuji Yoshikawa,Kuniaki Sato,Tomoko Saito,Shuhei Ito,Takaaki Masuda,Atsushi Niida,Makoto Suzuki,Hideo Baba,Takashi Ito,Nobuyoshi Akimitsu,Yasuhiro Kodera,Koshi Mimori
摘要
The accurate and early diagnosis and classification of cancer origin from either tissue or liquid biopsy is crucial for selecting the appropriate treatment and reducing cancer-related mortality. Here, we established the CAncer Cell-of-Origin (CACO) methylation panel using the methylation data of the 28 types of cancer in The Cancer Genome Atlas (7950 patients and 707 normal controls) as well as healthy whole blood samples (95 subjects). We showed that the CACO methylation panel had high diagnostic potential with high sensitivity and specificity in the discovery (maximum AUC = 0.998) and validation (maximum AUC = 1.000) cohorts. Moreover, we confirmed that the CACO methylation panel could identify the cancer cell type of origin using the methylation profile from liquid as well as tissue biopsy, including primary, metastatic, and multiregional cancer samples and cancer of unknown primary, independent of the methylation analysis platform and specimen preparation method. Together, the CACO methylation panel can be a powerful tool for the classification and diagnosis of cancer.